52853
7α-Hydroxy-4-cholesten-3-one
≥95.0% (HPLC)
Synonym(s):
7α-Hydroxycholest-4-en-3-one
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C27H44O2
CAS Number:
Molecular Weight:
400.64
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
grade
analytical standard
Quality Level
assay
≥95.0% (HPLC)
application(s)
clinical testing
format
neat
storage temp.
−20°C
SMILES string
O=C1CC[C@@]2(C)C(C[C@@H](O)[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@H](C)CCCC(C)C)=C1
InChI
1S/C27H44O2/c1-17(2)7-6-8-18(3)21-9-10-22-25-23(12-14-27(21,22)5)26(4)13-11-20(28)15-19(26)16-24(25)29/h15,17-18,21-25,29H,6-14,16H2,1-5H3/t18-,21-,22+,23+,24-,25+,26+,27-/m1/s1
InChI key
IOIZWEJGGCZDOL-RQDYSCIWSA-N
General description
7α-Hydroxy-4-cholesten-3-one (C4) is known as a marker for the cholesterol 7α-hydroxylase activity. It plays an important role in bile acid metabolism.
Application
C4 may be used as a reference standard for the determination of C4 in:
- Human serum by ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) with electrospray ionization source (ESI) as well as LC-MS.
- Rat and monkey plasma by LC-ESI-MS/MS working on multiple reaction monitoring (MRM) mode of detection.
- Peripheral blood plasma by solid-phase extraction (SPE) and HPLC.
Biochem/physiol Actions
7a-Hydroxycholestene-3-one, a metabolite in bile acid synthesis, is derived from 7a-hydroxycholesterol and can be further metabolized to 7a,12a,-dihydroxycholest-4-en-3-one. Analysis of 7a-Hydroxycholestene-3-one (HCO) in serum may serve as a novel, simple, and sensitive method for the detection of bile acid malabsorption in patients with chronic diarrhea of unknown origin.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Marcos Pedrosa et al.
Contemporary clinical trials, 88, 105889-105889 (2019-11-16)
Nonalcoholic steatohepatitis (NASH) is a multifactorial disease involving different contributing mechanisms, with no approved therapies so far. Tropifexor (TXR), a farnesoid X receptor agonist, and cenicriviroc (CVC), a chemokine receptor types 2/5 antagonist, target the steatotic, inflammatory, and/or fibrotic pathways
LC-MS/MS quantification of 7?-hydroxy-4-cholesten-3-one (C4) in rat and monkey plasma.
Kang L, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications, 1064, 49-55 (2017)
C G Hillebrant et al.
European journal of clinical investigation, 28(4), 324-328 (1998-06-06)
HMG-CoA reductase inhibitors are now the therapy of choice in the treatment of hypercholesterolaemia. The effects of long-term treatment with these substances on plasma lipoproteins, cholesterol metabolism and biliary secretion of lipids have been extensively studied in humans. Much less
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 630950-1G | 04061825771335 |
| 52853-1MG | 04061826231838 |
| 52853-5MG | 04061833457306 |